Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-01
2006-08-01
O'Sullivan, Peter (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S373000
Reexamination Certificate
active
07084143
ABSTRACT:
The invention relates to compounds of formula (I) wherein R1, R2, R4and R5have the meaning given in Claim1. Said compounds are potent 5-HT2A-antagonists and are suitable for the treatment of psychosis, schizophrenia, depression, neurological disorders, memory disorders. Parkinson's disease, amytrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders, e.g. nervous bulimia and anorexia and premenstrual syndrome and/or for positively influencing compulsive behaviors (obsessive-compulsive disorder, OCD).
REFERENCES:
patent: 6218394 (2001-04-01), Perregaard et al.
patent: 0 559 240 (1994-06-01), None
patent: 03 209 83 (1995-06-01), None
patent: P9603371 (1997-09-01), None
patent: WO 99 11 641 (1999-03-01), None
Robichaud et al., Annual Reports in Medicinal Chemistry, vol. 35, pp. 11-20 (2000).
Written Opinion in corresponding PCT application which cites EP 599,240, 1994.
Boettcher Henning
Seyfried Christoph
Merck Patent GmbH
Millen White Zelano & Branigan P.C.
O'Sullivan Peter
LandOfFree
N-(indolecarbonyl) piperazine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-(indolecarbonyl) piperazine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-(indolecarbonyl) piperazine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3692474